Loading...
DOCUMENTS
NOTICES
MOTS CLES
Monitoring
DNA METHYLATION
Over 80s
Crohn's disease
Eradication
Genes
RISK
Epigenetics
Patient-reported outcome
Small molecules
Colon
Maintenance therapy
Colonic epithelial primary cells
Gene expression
Disability
IBD
Stricture
Inflammatory bowel disease
Ustekinumab
Anti-TNF
Clinical guidelines
Tailored therapy
Survival
Cost effectiveness
IL12
Microbiota
MORTALITY
Helicobacter pylori
Bactéries
Colorectal cancer
Inflammatory Bowel Diseases
Drug
Colectomy
Immunosuppressant
Colorectal cancer Colibactin and lipids
Anti-TNF agents
IL23
Inclusion
Screening
MARKER
Cell adhesion
Intestinal crypts
Cancer
Vedolizumab
Crohn’s disease
Neoadjuvant chemotherapy
Inhibitor
Patients experience
Bacteria
Microbiote
Immune cells
DNA methylation
Algorithm
Biologics
Gene methylation
Colon cancer
Upper gastrointestinal tract
COLON-CANCER
Parvimonas micra
Inflammatory bowel diseases
Kidney diseases
Thérapie ciblée
Methylation
PCR
MICROBIOTA
Biomarker
HIV
Ulcerative colitis
Clinical trial
Consensus
Contraindication
CARCINOGENESIS
Therapeutics
Acceptability
Gènes
Safety
Tuberculosis
Endoscopic treatment
18 FDG-PET/CT
Fecal microbiota
Dysbiosis
T1118 translocation
Surgery
Epigénétiques
Venous thromboembolism
Rituximab plus chlorambucil
MALT
Original Article Clinical
Rituximab
Résistance
Méthylation
Dysbiose
Heart disease risk factors
Effectiveness
Disease progression
Resistance
Primary sclerosing cholangitis
Eligibility
Disease Progression
Alkylating agents
Early detection of Colon Cancer using Molecular Markers and Microbiota , EA 7375 | |
---|---|
Institutions |
UPEC |
Adresse |
Université Paris-Est Créteil Groupe Hospitalier Henri Mondor Service de Gastroentérologie 51 Av Maréchal de Lattre de Tassigny 94010 Créteil cedex |
Courriel |
|
Site Internet |
|
Rattachement(s) |
|
Direction |
Aurélien AMIOT |
Adjoint |
Iradj SOBHANI |
Axe(s) de recherche
|
Le laboratoire axe ses recherches sur le rôle du microbiome intestinal ainsi que des changements épigénétiques dans l'intestin afin :
|